BACKGROUND: The EPI-SCAN study (Epidemiologic Study of COPD in Spain), conducted from May 2006 to July 2007, determined that the prevalence of COPD in Spain according to the GOLD criteria was 10.2% of the 40 to 80 years population. Little is known about the current geographical variation of COPD in Spain. OBJECTIVES: We studied the prevalence of COPD, its under-diagnosis and under-treatment, smoking and mortality in the eleven areas participating in EPI-SCAN. COPD was defined as a post-bronchodilator FEV₁/FVC ratio <0.70 or as the lower limit of normal (LLN). RESULTS: The ratio of prevalences of COPD among the EPI-SCAN areas was 2.7-fold, with a peak in Asturias (16.9%) and a minimum in Burgos (6.2 %) (P<0.05). The prevalence of COPD according to LLN was 5.6% (95% CI 4.9-6.4) and the ratio of COPD prevalence using LLN was 3.1-fold, but with a peak in Madrid-La Princesa (10.1%) and a minimum in Burgos (3.2%) (P<0.05). The ranking of prevalences of COPD was not maintained in both sexes or age groups in each area. Variations in under-diagnosis (58.6% to 72.8%) and under-treatment by areas (24.1% to 72.5%) were substantial (P<0.05). The prevalence of smokers and former smokers, and cumulative exposure as measured by pack-years, and the age structure of each of the areas did not explain much of the variability by geographic areas. Nor is there any relation with mortality rates published by Autonomous Communities. CONCLUSION: There are significant variations in the distribution of COPD in Spain, either in prevalence or in under-diagnosis and under-treatment.
BACKGROUND: The EPI-SCAN study (Epidemiologic Study of COPD in Spain), conducted from May 2006 to July 2007, determined that the prevalence of COPD in Spain according to the GOLD criteria was 10.2% of the 40 to 80 years population. Little is known about the current geographical variation of COPD in Spain. OBJECTIVES: We studied the prevalence of COPD, its under-diagnosis and under-treatment, smoking and mortality in the eleven areas participating in EPI-SCAN. COPD was defined as a post-bronchodilator FEV₁/FVC ratio <0.70 or as the lower limit of normal (LLN). RESULTS: The ratio of prevalences of COPD among the EPI-SCAN areas was 2.7-fold, with a peak in Asturias (16.9%) and a minimum in Burgos (6.2 %) (P<0.05). The prevalence of COPD according to LLN was 5.6% (95% CI 4.9-6.4) and the ratio of COPD prevalence using LLN was 3.1-fold, but with a peak in Madrid-La Princesa (10.1%) and a minimum in Burgos (3.2%) (P<0.05). The ranking of prevalences of COPD was not maintained in both sexes or age groups in each area. Variations in under-diagnosis (58.6% to 72.8%) and under-treatment by areas (24.1% to 72.5%) were substantial (P<0.05). The prevalence of smokers and former smokers, and cumulative exposure as measured by pack-years, and the age structure of each of the areas did not explain much of the variability by geographic areas. Nor is there any relation with mortality rates published by Autonomous Communities. CONCLUSION: There are significant variations in the distribution of COPD in Spain, either in prevalence or in under-diagnosis and under-treatment.
Authors: Tracy A Lieu; David Au; Jerry A Krishnan; Marc Moss; Harry Selker; Andrea Harabin; Virginia Taggart; Alfred Connors Journal: Am J Respir Crit Care Med Date: 2011-10-01 Impact factor: 21.405
Authors: Verónica Casado; Sandra M Navarro; Andrés E Alvarez; Mercedes Villafañe; Ana Miranda; Natalia Spaans Journal: Ann Fam Med Date: 2015 Jan-Feb Impact factor: 5.166
Authors: Wouter van Dijk; Wan Tan; Pei Li; Best Guo; Summer Li; Andrea Benedetti; Jean Bourbeau Journal: Ann Fam Med Date: 2015 Jan-Feb Impact factor: 5.166
Authors: Eva Balcells; Elena Gimeno-Santos; Jordi de Batlle; Maria Antonia Ramon; Esther Rodríguez; Marta Benet; Eva Farrero; Antoni Ferrer; Stefano Guerra; Jaume Ferrer; Jaume Sauleda; Joan A Barberà; Àlvar Agustí; Robert Rodriguez-Roisin; Joaquim Gea; Josep M Antó; Judith Garcia-Aymerich Journal: BMC Pulm Med Date: 2015-01-17 Impact factor: 3.317
Authors: José Leiva-Fernández; Francisca Leiva-Fernández; Antonio García-Ruiz; Daniel Prados-Torres; Pilar Barnestein-Fonseca Journal: BMC Pulm Med Date: 2014-04-25 Impact factor: 3.317
Authors: Hanaa F Elkhenini; Kourtney J Davis; Norman D Stein; John P New; Mark R Delderfield; Martin Gibson; Jorgen Vestbo; Ashley Woodcock; Nawar Diar Bakerly Journal: BMC Med Inform Decis Mak Date: 2015-02-07 Impact factor: 2.796
Authors: Josep Darbà; Gabriela Ramírez; Juan L García-Rivero; Sagrario Mayoralas; José Francisco Pascual; Diego Vargas; Adi Bijedic Journal: Clinicoecon Outcomes Res Date: 2017-02-10